Protein tyrosine phosphatase 2 (SHP-2) has long been proposed as a cancer drug target.
Several small-molecule compounds with different mechanisms of SHP-2 inhibition have been reported,
but none are commercially available. Pool selectivity over protein tyrosine phosphatase 1 (SHP-1)
and a lack of cellular activity have hindered the development of selective SHP-2 inhibitors. In this review,
we describe the binding modes of existing inhibitors and SHP-2 binding sites, summarize the
characteristics of the sites involved in selectivity, and identify the suitable groups for interaction with
the binding sites.
Keywords: PTP, SHP-2, SHP-1, protein tyrosine kinases, PTKs, cancer.
Rights & PermissionsPrintExport